GoalFusion Wealth Management’s Recursion Pharmaceuticals RXRX Stock Holding History

GoalFusion Wealth Management’s Portfolio RXRX Stock Details RXRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-20,000	Closed	-$197K	–	31
2023 Q4	$197K	Hold	20,000	–	–	0.13%	28
2023 Q3	$153K	Hold	20,000	–	–	0.11%	27
2023 Q2	$149K	Hold	20,000	–	–	0.11%	26
2023 Q1	$133K	Hold	20,000	–	–	0.1%	22
2022 Q4	$167K	Hold	20,000	–	–	0.13%	20
2022 Q3	$213K	Sell	20,000 -4,000	-17%	-$40.5K	0.2%	16
2022 Q2	$195K	Sell	24,000 -30,000	-56%	-$201K	0.18%	17
2022 Q1	$387K	Buy	+54,000	New	+$574K	0.33%	15

Other funds holding RXRX

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

MIC

Mubadala Investment Company Abu Dhabi, United Arab Emirates $20.5B AUM 19.39% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Kinnevik AB Stockholm, Sweden $65.6M AUM 25.95% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

GoalFusion Wealth Management's RXRX Position: Q1 2024 in Review

GoalFusion Wealth Management sold out of Recursion Pharmaceuticals (RXRX) in Q1 2024, closing a stake of 20,000 shares — an estimated $197K sold.

GoalFusion Wealth Management first reported a position in RXRX in Q1 2022 and held it in 8 quarters. The position peaked at $387K in Q1 2022. 249 funds tracked by Wall St. Rank hold RXRX as of Q1 2024.

GoalFusion Wealth Management reported no remaining Recursion Pharmaceuticals position as of Q1 2024 after selling out during the quarter.
GoalFusion Wealth Management sold 20,000 Recursion Pharmaceuticals shares in Q1 2024, an estimated $197K.
GoalFusion Wealth Management first reported a position in Recursion Pharmaceuticals in Q1 2022 and held it in 8 quarters.
GoalFusion Wealth Management's Recursion Pharmaceuticals position peaked at $387K in Q1 2022.
249 funds tracked by Wall St. Rank held Recursion Pharmaceuticals as of Q1 2024.

Based on GoalFusion Wealth Management's 13F filing for Q1 2024, filed 3 Apr 2024.